About this Event
Location: Serengeti | 6th floor at Broad Institute | 75 Ames Strees
Do you ever see those large Series A announcements and wonder how much equity the academic founders actually own? They usually don't own much.
On June 26th, Curie.Bio will provide an overview of what goes into building a successful early-stage therapeutics company. You'll come away with a better understanding of how to think about selecting the right therapeutic applications, how to set the right milestones, and how that impacts the dilution of founder ownership and the probability of success for your company. Curie.Bio has created a model where founders get access to a world-class team of drug hunters and biotech operators that help founders identify the best possible value creation path for their ideas and then execute on that path in a capital-efficient manner. This leads to founders retaining significant upside in their company and having a higher chance of success in creating medicines that impact patients. Their first case study is here.
Curie.Bio Attendees:
- George Voren - Head of Founder Strategy and Operations, former Flagship Pioneering and Relay Tx
- Greg Carven - Partner, former CSO of Scholar Rock and co-inventor of Keytruda
- Raven Reddy - VP of Founder Strategy and Operations, former BridgeBio and Dementia Discovery Fund
Agenda
3:00-4:00pm: Curie.Bio seminar
- What impacts a founder's ownership and control in their company?
- What does it take to translate a scientific concept into a successful therapeutics company?
- How does Curie.Bio help founders win?
4:00-5:00pm: Networking reception with food and drinks
Event Venue & Nearby Stays
Serengeti | 6th floor, 75 Ames Street, Cambridge, United States
USD 0.00
